Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFTISARC-NEO: Pembrolizumab, Eftilagimod Alfa, and Radiotherapy in Neoadjuvant Soft Tissue Sarcoma
NCT06128863Phase 2Active, not recruiting
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Jul 2023
- Primary completion
- Apr 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eftilagimod alpha in soft tissue sarcoma (STS), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Started Jul 2023; status: active, not recruiting.
02
Drugs
eftilagimod alpha
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06128863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128863.